ALK-Abello rises on regulatory news and strong financial results

Shares of Denmark’s ALK-Abello (ALK: DC) were up 7.9% at 110.90 Danish kroner by early afternoon, as the allergy immunotherapy company announced 2022 financial results and acceptance of a regulatory filing in China.

ALK said that Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (AIT) tablet has been accepted for review by the National Medical Products Administration (NMPA) in China. The BLA, for treatment of persistent moderate-to-severe HDM allergic rhinitis in patients aged 12–65 was submitted in late December 2022.

Søren Niegel, ALK's executive vice president, commercial operations, says: “This is an important step forward for ALK’s efforts to bring new, evidence-based treatment options to the millions of people with moderate to severe allergy and their doctors in China asking for better solutions. In line with our previously communicated plans, we are investing in better allergy care with great determination in China, and we see a potential future launch of our Acarizax tablet, the first AIT tablet in China, as an important contributor to our long-term growth ambitions.”